A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin

Healthy Participants Clinical Trial

Official title:

A Fixed Sequence, Open-label Study to Assess the Effect of Multiple Doses of AZD5462 on the Pharmacokinetics of Oral Midazolam (CYP3A4 Probe), Rosuvastatin (OATP1B1/3, BCRP Probe), and Digoxin (P-gp Probe) in Healthy Participants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05395117
• Other study ID #: D9090C00003
• Status: Completed
• Phase: Phase 1
• Start date: June 30, 2022
• Est. completion date: September 12, 2022

Study information

• Verified date: December 2023
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will assess the effect of multiple doses of AZD5462 on the PK of oral midazolam (CYP3A4 probe), rosuvastatin (OATP1B1/3, BCRP probe), and digoxin (P-gp probe) in healthy participants.

This study will consist of 2 treatment arms (Treatment Arms A and B) and within each treatment arm, the participants will first be administered the probe substrates (midazolam, rosuvastatin, and digoxin) alone followed by administration of the probe substrates together with AZD5462. The treatment arms differ in the dose of AZD5462 being administered and will be performed sequentially starting with Treatment Arm A (AZD5462 Dose A, high dose treatment arm) and followed by Treatment Arm B (AZD5462 Dose B, low dose treatment arm). Each treatment arm will include 5 periods.

Thirty two participants in total (16 participants per treatment arm) will be enrolled to ensure at least 24 evaluable participants (12 participants per treatment arm) at the end of the last treatment period.

A follow-up visit at Day 24 (+-1 Day) will be conducted via a phone call.

Description:

This is a phase I, single-centre, 2-treatment arm, 5-period, fixed sequence study.

The Study Will Comprise of a Screening Period and Five Treatment Periods:

• Screening Period (Maximum 28 Days) Participant eligibility will be confirmed during the Screening Visit.

• Period 1 (Day 1) Single dose administration of midazolam on Day 1.

• Period 2 (Day 2) Single dose administration of rosuvastatin and digoxin on Day 2. There will be a minimum washout period of 3 days between Period 2 and Period 3.

• Period 3 (Days 6 to 14) Single dose administration of rosuvastatin and digoxin together with AZD5462 (Treatment Arm A, Dose A; Treatment Arm B, Dose B) on Day 6. AZD5462 will continue to be administered throughout the period including Day 14.

• Period 4 (Day 15) Single dose administration of midazolam together with AZD5462 (Treatment Arm A, Dose A; Treatment Arm B, Dose B) at steady state on Day 15.

• Period 5 (Days 16 to 18) Single dose administration of rosuvastatin and digoxin together with AZD5462 (Treatment Arm A, Dose A; Treatment Arm B, Dose B) at steady state on Day

16. AZD5462 will continue to be administered on Days 17 and 18.

Participants will be resident in the study centre when dosed with probe substrates (midazolam, rosuvastatin, and digoxin) and/or AZD5462 including the washout period between Period 2 and Period 3. Residency will commence on Day -1 and end on Day 20.

A follow-up visit at Day 24 (+-1 Day) will be conducted via a phone call.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: September 12, 2022
• Est. primary completion date: September 12, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Provision of signed and dated, written informed consent prior to any study specific procedures.

• Healthy male and female participants aged 18 to 55 years with suitable veins for cannulation or repeated venepuncture.

• Females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating and must be of non childbearing potential confirmed at screening.

• Have a Body Mass Index (BMI) between 18 and 32 kg/m2 inclusive and weigh at least 50 kg and no more than 105 kg inclusive at screening.

• Male subject must adhere to the contraception methods details.

Exclusion Criteria:

• History of any clinically significant disease or disorder which may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study including but not limited to:

(i) Systemic sclerosis (ie, scleroderma). (ii) Moderate to severe valvular disease. (iii) Hypertrophic obstructive cardiomyopathy. (iv) Restrictive cardiomyopathy. (v) Gilbert's syndrome. (vi) History of vascular or left ventricular aneurysms or prior dissections. (vii) Any history of joint hypermobility, Marfan's Syndrome, or any connective tissue disorder.

• History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.

• Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMPs.

• Any laboratory values with deviations at screening or admission to the study centre.

• Any clinically significant abnormalities in clinical biochemistry, haematology, or urinalysis results.

• Any clinically significant abnormal findings in vital signs after 5 minutes supine rest.

• Any clinically important abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically important abnormalities in the 12-lead ECG.

• Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.

• Known or suspected history of drug abuse.

• Has received another new chemical entity within 3 months of the first administration of IMP in this study.

• Plasma donation within 1 month of screening or any blood donation/loss > 500 mL during the 3 months prior to screening.

• History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD5462.

• Current smokers or those who have smoked or used nicotine products within the 3 months prior to screening.

• Positive screen for drugs of abuse or cotinine at screening or on each admission to the study centre or positive screen for alcohol on admission to the study centre prior to the first administration of the IMP.

• Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.

• Use of any prescribed or non prescribed medication including antacids, analgesics, herbal remedies, megadose vitamins and minerals during the 2 weeks or 5 half-lives of the medication, whichever is longer, prior to the first administration of IMP.

• Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.

• Excessive intake of caffeine-containing drinks or food.

• Involvement of any AstraZeneca, Parexel, or study centre employee or their close relatives.

• Participants who have previously received AZD5462.

• Participants who are vegans or have medical dietary restrictions.

• Vulnerable participants.

• Participants who cannot communicate reliably with the Principal Investigator (PI).

• Clinical signs and symptoms consistent with COVID-19 by appropriate laboratory test within the last 4 weeks prior to screening or on admission.

Related Conditions & MeSH terms

• Healthy Participants

Intervention

Drug:
• AZD5462
Treatment Arm A: Participants will receive the IMP, AZD5462 Dose A starting on Day 6 and continued until Day 18 and the following approved medicinal products: Midazolam Rosuvastatin Digoxin Treatment Arm B: Participants will receive the IMP, AZD5462 Dose B starting on Day 6 and continued until Day 18 and the following approved medicinal products: Midazolam Rosuvastatin Digoxin
• Midazolam
Participants will receive a single dose of midazolam in the morning of Day 1 and in the morning of Day 15 in both the arms.
• Rosuvastatin
Participants will receive rosuvastatin as a single dose administered with digoxin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.
• Digoxin
Participants will receive digoxin as a single dose administered with rosuvastatin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.

Locations

Country	Name	City	State
United States	Research Site	Brooklyn	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
AstraZeneca	Parexel

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the concentration-versus-time curve from pre-dose (time 0) extrapolated to infinite time (AUCinf)	The effect of AZD5462 on the AUCinf of oral midazolam, rosuvastatin, and digoxin will be assessed.	Midazolam: Period 1 (Day 1), and Period 4 (Day 15); Rosuvastatin and Digoxin: Period 2 (Day 2), Period 3 (Days 6 - 14), and Period 5 (Days 16 - 18)
Primary	Area under the concentration-versus-time curve from pre-dose (time 0) to the time of the last quantifiable concentration (AUClast)	The effect of AZD5462 on the AUClast of oral midazolam, rosuvastatin, and digoxin will be assessed.	Midazolam: Period 1 (Day 1), and Period 4 (Day 15); Rosuvastatin and Digoxin: Period 2 (Day 2), Period 3 (Days 6 - 14), and Period 5 (Days 16 - 18)
Primary	Maximum observed serum (peak) drug concentration [Cmax]	The effect of AZD5462 on the Cmax of oral midazolam, rosuvastatin, and digoxin will be assessed.	Midazolam: Period 1 (Day 1), and Period 4 (Day 15); Rosuvastatin and Digoxin: Period 2 (Day 2), Period 3 (Days 6 - 14), and Period 5 (Days 16 - 18)
Secondary	Time to reach peak or maximum observed concentration or response following drug administration (tmax)	The effect of AZD5462 on the tmax of oral midazolam, rosuvastatin, and digoxin will be assessed.	Midazolam: Period 1 (Day 1), and Period 4 (Day 15); Rosuvastatin and Digoxin: Period 2 (Day 2), Period 3 (Days 6 - 14), and Period 5 (Days 16 - 18)
Secondary	Half life associated with terminal slope (?z) of a semi logarithmic concentration time curve (t1/2?z)	The effect of AZD5462 on the t1/2?z of oral midazolam, rosuvastatin, and digoxin will be assessed.	Midazolam: Period 1 (Day 1), and Period 4 (Day 15); Rosuvastatin and Digoxin: Period 2 (Day 2), Period 3 (Days 6 - 14), and Period 5 (Days 16 - 18)
Secondary	Partial area under the serum concentration time curve from time 0 to time 12 (AUC0-12h)	The AUC0-12h of AZD5462 will be determined.	Day 6, and Day 16
Secondary	Maximum observed serum (peak) drug concentration [Cmax]	The Cmax of AZD5462 will be determined.	Day 6, and Day 16
Secondary	Time to reach peak or maximum observed concentration or response following drug administration (tmax)	The tmax of AZD5462 will be determined.	Day 6, and Day 16
Secondary	Trough plasma exposure of AZD5462 (Ctrough)	Ctrough values of AZD5462 will be determined.	Days 14 to 15, and Days 17 to 18
Secondary	Incidence of Adverse Events (AEs)	The safety and tolerability of AZD5462 alone and in combination with midazolam, rosuvastatin, and digoxin will be examined.	From screening (Day -28 to Day -2) to follow-up (Day 20)